Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

NCT02628613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Vinorelbine plus Epirubicin
DRUG: Paclitaxel plus Epirubicin

Sponsor

Fudan University